Last reviewed · How we verify
UGT1A1 victim drug — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
UGT1A1 victim drug (UGT1A1 victim drug) — Kadmon, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| UGT1A1 victim drug TARGET | UGT1A1 victim drug | Kadmon, a Sanofi Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- UGT1A1 victim drug CI watch — RSS
- UGT1A1 victim drug CI watch — Atom
- UGT1A1 victim drug CI watch — JSON
- UGT1A1 victim drug alone — RSS
Cite this brief
Drug Landscape (2026). UGT1A1 victim drug — Competitive Intelligence Brief. https://druglandscape.com/ci/ugt1a1-victim-drug. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab